Telbivudine - Novartis
Alternative Names: 2'-deoxy-L-thymidine; B-L-thymidine; Beta-L-thymidine; Epavudine; L-dT; LDT-600; NV-02B; Sebivo; TyzekaLatest Information Update: 27 Dec 2021
At a glance
- Originator Centre National de la Recherche Scientifique; Idenix Pharmaceuticals; University of Montpellier II
- Developer Novartis
- Class Antivirals; Nucleosides; Pyrimidines; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis B
Most Recent Events
- 14 Apr 2021 No development reported - Phase-III for Hepatitis B (In adolescents) in Bulgaria (PO)
- 14 Apr 2021 No development reported - Phase-III for Hepatitis B (In adolescents) in Greece (PO)
- 14 Apr 2021 No development reported - Phase-III for Hepatitis B (In adolescents) in Israel (PO)